机构：[1]Department of Gynaecology and Obstetrics, Jinan City People's Hospital, Jinan, China.[2]Department of Laboratory Medicine, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China.[3]Department of Gynaecology and Obstetrics, Liaocheng People's Hospital, Liaocheng, China.[4]Department of Pharmacy, Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.[5]Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Circular RNA (circRNA) is considered to be an important regulator that mediates cancer chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin (DDP) resistance is unclear. The circ-LPAR3, miR-634 and pyruvate dehydrogenase kinase 1 (PDK1) expression was measured by quantitative real-time PCR (qRT-PCR). Cell cisplatin resistance and viability were measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. In addition, cell colony number, apoptosis, and metastasis were assessed by colony formation assay, flow cytometry and transwell assay. Furthermore, in vivo experiments were performed by constructing mice xenograft models. RNA interaction was confirmed by dual-luciferase reporter assay, and PDK1 protein expression was examined by Western blot analysis. Our results showed that circ-LPAR3 was markedly upregulated in DDP-resistant OC tissues and cells. Silencing of circ-LPAR3 enhanced the DDP sensitivity of OC cells and tumors. MiR-634 could interact with circ-LPAR3, and its inhibitor overturned the regulation of si-circ-LPAR3 on cell DDP resistance. Additionally, PDK1 was targeted by miR-634, and its overexpression inverted the effect of miR-634 on cell DDP resistance. To sum up, circ-LPAR3 might contribute to the DDP resistance of OC via the miR-634/PDK1 axis.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区生物学
小类|2 区生物工程与应用微生物
最新[2023]版：
大类|4 区生物学
小类|4 区生物工程与应用微生物
第一作者：
第一作者机构：[1]Department of Gynaecology and Obstetrics, Jinan City People's Hospital, Jinan, China.
共同第一作者：
通讯作者：
通讯机构：[4]Department of Pharmacy, Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.[5]Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.[*1]Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, 13 Wuhe Avenue, Qingxiu District, Nanning, Guangxi 530222, China[*2]Department of Gynecology
推荐引用方式(GB/T 7714)：
Liu Xuemei,Yin Zhiping,Wu Yanjun,et al.Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer[J].Bioengineered.2022,13(2):3739-3750.doi:10.1080/21655979.2022.2029109.
APA：
Liu Xuemei,Yin Zhiping,Wu Yanjun,Zhan Qian,Huang Honghong&Fan Jiangtao.(2022).Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer.Bioengineered,13,(2)
MLA：
Liu Xuemei,et al."Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer".Bioengineered 13..2(2022):3739-3750
